Phase 2 N=33 Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI)
Persian Gulf Syndrome
Primary: Effect of Carnosine Supplementation on Chronic Fatigue Syndrome Severity Scores — -3.8; -2.0 units on a scale — p=0.30
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
Leukemia
Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…
Phase 2 N=87 Rituximab in New Onset Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a 4-hour Mixed Meal Tolerance Test (MMTT) Administered at 1 Year — 0.58; 0.429 pmol per mL — p=0.05
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Phase 2 N=31 Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer
Biliary Tract Cancer · Gallbladder Cancer
Primary: The Number of Participants With Response to GEMOX-Panitumumab (GEMOX-P) in Chemotherapy naïve KRAS/ BRAF Wild Type Stage IV Biliary Tract Cancer Using the Response…
Phase 2 N=231 Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO
Non Small Cell Lung Cancer (NSCLC)
Primary: Percentage of Participants With Select Dermatologic Adverse Events of Interest (SDAEI) (All Causality, All Grade) in the First 8 Weeks of Treatment by Treatment Arm for…
Phase 2 N=112 Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus
Type 1 Diabetes Mellitus
Primary: Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 2 Year Visit — 0.375; 0.266 nmol/L — p=0.0014
Phase 2 N=103 Leptin to Treat Lipodystrophy
Lipodystrophy
Primary: Percentage of Glycosylated Hemoglobin at Baseline, 6 Months, and 12 Months on Treatment With Metreleptin — 8.4; 8.1; 6.6; 7.2 percentage of glycated hemoglobin — p=<0.001
Phase 2 N=71 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Lung Cancer
Primary: Mediastinal Nodal Clearance After Completion of Induction Chemoradiotherapy With or Without Panitumumab. — 68.2; 48.7 percentage of participants — p=0.96
Phase 2 N=130 A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer
Thrombosis · Cancer · Pulmonary Embolism
Primary: Number of Participants With Composite of Confirmed Major Bleeding and Clinically Relevant Nonmajor (CRNM) Bleeding — 1; 1; 1; 4 Participants
Phase 2 N=114 New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial
Diabetes Mellitus, Type 1
Primary: Mean Stimulated C-peptide Area Under the Curve — 0.28; 0.27; 0.25 pmol/ml — p=0.47
Phase 2 N=350 Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline in NPI-C Combined Agitation and Aggression Subscores (NPI-C A+A). — -4.3; -4.2 units on a scale
Phase 2 N=36 Locomotor Training in Persons With Multiple Sclerosis
Multiple Sclerosis
Primary: Walking Speed as Assessed by 25' Timed Walk — 22.7; 10.6; 23.9; 9.8 seconds
Phase 2 N=14 Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury
Pediatric Traumatic Brain Injury
Primary: Number of Participants Who Experienced Adverse Events — 0; 2 participants
Phase 2 N=40 Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
Breast Cancer
Primary: Time to Progression (TTP) in Women With Hormone Responsive Advanced Breast Cancer Treated With Combination of Exemestane and Fulvestrant. — 6.9 months